Renal Cell Carcinoma (RCC) is the most common form of kidney cancer in the urinary system. RCC can be divided into different histopathological subtypes, such as clear-cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chRCC) and a number of other rare subtypes. When compared to other cancers in the urinary system most RCC cases have a better prognosis however, the morbidity and mortality rates of RCC have increased significantly, especially in young patients and those with high-grade tumors. The treatment of metastatic RCC remains a challenge as a majority of ccRCC cells show resistance to chemotherapy and radiotherapy. Therefore, studying the cellular molecular characteristics of RCC is important to provide guidance for clinical treatment and insight into treatment of difficult cases.
There have been many advancements in RCC treatment over the years with early surgical resection and novel tyrosine kinase inhibitor immunotherapy using antibodies to checkpoint block inhibitors alone and in combination (anti-PD1 or anti-CTLA4). Advancements in molecular genetics and therapeutics of RCC have continued to look into understanding the molecular mechanisms of RCC to help improve the outcome and survival of patients who present with the most severe cases. Recent studies focussing on genomic analysis, analysis using single-cell RNA seq, qRT-PCR has helped identify cellular molecular characteristics of RCC with potential treatment options. Identifying new lncRNAs, miRNAs and unique genetic signatures have exhibited good application prospects in biomarker development and the treatment of cancer and may become new treatment targets for cancer. This Research topic focuses on advancements of molecular genetics and the potential for improvements in treatment.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advancements of molecular genetics and therapeutics in Renal Carcinoma.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Renal Cell Carcinoma (RCC) is the most common form of kidney cancer in the urinary system. RCC can be divided into different histopathological subtypes, such as clear-cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chRCC) and a number of other rare subtypes. When compared to other cancers in the urinary system most RCC cases have a better prognosis however, the morbidity and mortality rates of RCC have increased significantly, especially in young patients and those with high-grade tumors. The treatment of metastatic RCC remains a challenge as a majority of ccRCC cells show resistance to chemotherapy and radiotherapy. Therefore, studying the cellular molecular characteristics of RCC is important to provide guidance for clinical treatment and insight into treatment of difficult cases.
There have been many advancements in RCC treatment over the years with early surgical resection and novel tyrosine kinase inhibitor immunotherapy using antibodies to checkpoint block inhibitors alone and in combination (anti-PD1 or anti-CTLA4). Advancements in molecular genetics and therapeutics of RCC have continued to look into understanding the molecular mechanisms of RCC to help improve the outcome and survival of patients who present with the most severe cases. Recent studies focussing on genomic analysis, analysis using single-cell RNA seq, qRT-PCR has helped identify cellular molecular characteristics of RCC with potential treatment options. Identifying new lncRNAs, miRNAs and unique genetic signatures have exhibited good application prospects in biomarker development and the treatment of cancer and may become new treatment targets for cancer. This Research topic focuses on advancements of molecular genetics and the potential for improvements in treatment.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advancements of molecular genetics and therapeutics in Renal Carcinoma.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
